Change theme to redChange theme to blueChange theme to greenChoose your color
 

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil



LIPOSOMES CONTAINING NOVEL TARGETING AND/OR FUSOGENIC PEPTIDES, PREPARATION CONTAINING THEM AND THERAPEUTIC USE THEREOF

A novel targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR .sctn.1.72(b).


Docket:WRAIR 2003-66

Publication/Issued No.:7,741,431

Publication/Issue Date:2006-01-25

Categories: Device

More Detail:Visit USPTO.GOVExternal link

Lab:WRAIR

Inventor(s):ALLON, N.; CHAMBERS, C.; SAXENA, A.; DOCTOR, B.


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRMC Public Affairs Office at:
usarmy.detrick.medcom-usamrmc.list.webmaster@mail.mil or by telephone at (301)619-2736